Archive for the ‘Viral Vaccines’ Category

BioReliance to Host Complimentary Seminars in Europe Next Week

Wednesday, March 6th, 2013

BioReliance looks forward to hosting the upcoming technical seminar: Essential Updates for Biologics Manufacturers. The seminar is available at the Radison Blu Royal Hotel in Copenhagen, Denmark on Tuesday, March 12th, 2013 and at the Renaissance Amsterdam Hotel in The Netherlands on Tuesday, March 19th, 2013.

As the leader in Biologics Safety Testing and Manufacturing Services, BioReliance hosts many complimentary seminars throughout the year. The events are aimed at providing customers and partners with the most up to date information in the industry. (more…)

Moving Forward with BioReliance by SAFC

Wednesday, February 6th, 2013

Last week, BioReliance President, Charlie Harwood shared information about the background of the company before it was purchased by Sigma-Aldrich, and a bit about what sets it apart. As we revisit the topic this week, Charlie offers a further look into the technologies behind the business and the future of the industry. (more…)

What to Expect from BioReliance by SAFC

Wednesday, January 30th, 2013

It has been a year since Sigma-Aldrich acquired testing specialist BioReliance. Its new logo, ‘BioReliance by SAFC’, was chosen to avoid losing customer recognition, while allowing SAFC to establish an identity and relationship with the business. Here, BioReliance President, Charlie Harwood offers a glimpse into the company’s history and activities – and what sets it apart from the competition.  (more…)

BioReliance by SAFC Gets Ready for Phacilitate in Washington DC

Wednesday, January 23rd, 2013

BioReliance by SAFC is looking forward to the Phacilitate Washington Vaccine Forum next week. We will be onsite from January 30th to February 1st at the Grand Hyatt in Washington, DC, and hope you can join us at Booth 51, where we will be available to talk about the latest trends in vaccine testing technology. (more…)

Best Wishes for a Prosperous New Year from SAFC

Friday, December 28th, 2012

2012 has been a busy and successful year for all of us at SAFC and we would like take a moment to thank you for your readership and input here on SAFC Live throughout the year. As the industry continues to change and grow, we are looking forward to a strong 2013 and to continuing to bring you industry information, interviews, news and more for the new year and beyond.

All of us at SAFC and SAFC Live extend our best wishes to you and yours for a prosperous new year. Please click here to view an animated card to you.

Patient Enrollment Confirmed for Phase I Clinical Trials of Reolysin in Combination with Folfiri

Tuesday, August 28th, 2012

As SAFC approached the end of 2011, we were honored to win an EOA award recognizing our partnership with Oncolytics as a commercial provider of reovirus to be used in the development of Oncolytics proprietary cancer treatment, Reolysin.

In the following piece, Peter Hofland reviews the next steps for Oncolytics as they confirm patient enrollment for Phase I clinical trials using Reolysin in combination with Folfiri to treat colorectal cancer patients. The full story can be found by clicking here.

To learn more about the full offering of SAFC CMO services, please click here.

Industry Insight with Chester: A Collection of Current Industry Updates

Friday, May 18th, 2012

Welcome to another posting of ‘Industry Insight with Chester,’ a periodic round-up of news and views from around the Pharma and biopharma industries compiled by Chester Solack, Business Analyst at SAFC in Lenexa, Kansas.

(more…)